Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-RIC trial of two reduced-intensity allogeneic transplant conditioning regimens in adults with acute lymphoblastic leukaemia
ISRCTN99927695Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fludarabine, melphalan, alemtuzumab and cyclophosphamide in acute lymphoblastic leukemia (ALL), sponsored by University of Birmingham. Primary endpoint: Disease-free survival. Started Nov 2018; status: active, not recruiting.
02
Drugs
fludarabinemelphalanalemtuzumabcyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN99927695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99927695.